Clinical data | |
---|---|
Pronunciation | Everolimus /ˌɛvəˈroʊləməs/ |
Trade names | Afinitor, Zortress |
Other names | 42-O-(2-hydroxyethyl)rapamycin, RAD001 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a609032 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | ~30 hours[9] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.149.896 |
Chemical and physical data | |
Formula | C53H83NO14 |
Molar mass | 958.240 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Everolimus, sold under the brand name Afinitor among others, is a medication used as an immunosuppressant to prevent rejection of organ transplants[10] and as a targeted therapy in the treatment of renal cell cancer and other tumours.[11]
This compound also has a use in cardiovascular drug-eluting stent technologies to inhibit restenosis.[medical citation needed]
It is the 40-O-(2-hydroxyethyl) derivative of sirolimus and works similarly to sirolimus as an inhibitor of mammalian target of rapamycin (mTOR).[12]
It is marketed by Novartis under the trade names Zortress (US) and Certican (European Union and other countries) in transplantation medicine, and as Afinitor (general tumours) and Votubia (tumours as a result of Tuberous Sclerosis Complex (TSC)) in oncology.[citation needed]
It is on the World Health Organization's List of Essential Medicines.[13] It is available as a generic medication.[14]
{{cite book}}
: |journal=
ignored (help)